Ribon Therapeutics

Executive Summary

Ribon Therapeutics is a clinical-stage biopharmaceutical company pioneering small molecule inhibitors of mono-ADP-ribosyltransferases (MARTs), a novel class of enzymes involved in cellular stress responses. The company's platform targets stressed cells selectively, offering potential in oncology and inflammatory diseases. Founded in 2015 and headquartered in Cambridge, MA, Ribon has raised approximately $25 million in funding. Its lead program is in Phase 2 development for solid tumors, with preclinical programs in immunology. The company's approach leverages the differential expression of MARTs in stressed versus normal cells, aiming to achieve a favorable therapeutic index. Despite being private and early-stage, Ribon's novel target class and initial clinical data support its potential in precision oncology. Ribon's scientific foundation is strong, with published research validating MARTs as therapeutic targets. The company faces typical biotech risks including clinical trial outcomes, competition from other stress-response pathway inhibitors, and funding needs for later-stage development. Key upcoming catalysts include initial efficacy data from its Phase 2 trial and potential partnership or licensing deals. The company's private status limits visibility, but its focused pipeline and differentiated mechanism position it as a potential acquisition target for larger oncology-focused firms. Conviction is moderate at 60, reflecting promising science balanced with early-stage execution risk.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 interim efficacy data readout in solid tumors55% success
• Q4 2026IND filing for second-generation MARTs inhibitor70% success
• H2 2026Potential strategic partnership or licensing deal40% success